Search

Your search keyword '"Chen, Shih-Hsiang"' showing total 466 results
Start Over Author "Chen, Shih-Hsiang"
466 results on '"Chen, Shih-Hsiang"'

9. Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan

Author

Liu, Hsi-Che, Kuo, Ming-Chung, Wu, Kang-Hsi, Chen, Tsai-Yun, Chen, Jiann-Shiuh, Wang, Ming-Chung, Lin, Tung-Liang, Yang, YoungSen, Ma, Ming-Chun, Wang, Po-Nan, Sheen, Jiunn-Ming, Wang, Shih-Chung, Chen, Shih-Hsiang, Jaing, Tang-Her, Cheng, Chao-Neng, Yeh, Ting-Chi, Lin, Tung-Huei, and Shih, Lee-Yung

Published
2023
Full Text
View/download PDF

15. Characteristics and outcomes of second cancers in patients with childhood cancer: A report from the Taiwan Pediatric Oncology Group

Author

Ho, Wan-Ling, Hung, Giun-Yi, Yen, Hsiu-Ju, Yang, Yung-Li, Chang, Hsiu-Hao, Lu, Meng-Yao, Lin, Kai-Hsin, Chen, Jiann-Shiuh, Cheng, Chao-Neng, Hung, Iou-Jih, Yang, Chao-Ping, Chen, Shih-Hsiang, Liu, Hsi-Che, Yeh, Ting-Chi, Hou, Jen-Yin, Hsiao, Chih-Cheng, Sheen, Jiunn-Ming, Chang, Tai-Tsung, Wong, Tai-Tong, Miser, James S., Liu, Yen-Lin, Chen, Rong-Long, Chen, Bow-Wen, Peng, Ching-Tien, Chang, Te-Kau, Wu, Kang-Hsi, Chang, Yu-Hsiang, Wang, Jinn-Li, Wang, Shih-Chung, Lin, Ming-Tsan, Hu, Fu-Chang, Jou, Shiann-Tarng, and Lin, Dong-Tsamn

Published
2022
Full Text
View/download PDF

18. Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity

Author

Liu, Hsi‐Che, primary, Huang, Ying‐Jung, additional, Jaing, Tang‐Her, additional, Wu, Kang‐Hsi, additional, Chen, Shih‐Hsiang, additional, Wang, Shih‐Chung, additional, Yeh, Ting‐Chi, additional, Hsiao, Chih‐Cheng, additional, Chang, Te‐Kau, additional, Yen, Hsiu‐Ju, additional, Huang, Fang‐Liang, additional, Lin, Pei‐Chin, additional, Hou, Jen‐Yin, additional, Sheen, Jiunn‐Ming, additional, Liao, Yu‐Mei, additional, Chang, Tsung‐Yen, additional, Chen, Yu‐Chieh, additional, Chiou, Shyh‐Shin, additional, Yang, Chao‐Ping, additional, Pui, Ching‐Hon, additional, Liang, Der‐Cherng, additional, and Shih, Lee‐Yung, additional

Published
2024
Full Text
View/download PDF

23. Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases.

Author

Wang, Yi-Lun, Chang, Tsung-Yen, Wen, Yu-Chuan, Yang, Shu-Ho, Hsiao, Yi-Wen, Chiu, Chia-Chi, Chen, Yu-Chieh, Hu, Ruei-Shan, Chen, Shih-Hsiang, Jaing, Tang-Her, and Hsiao, Chih-Cheng

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, HEMATOPOIETIC stem cell transplantation, CHILD patients, DISEASE relapse
Abstract

Background/Objectives: Relapsed B-cell acute lymphoblastic leukemia (B-ALL) remains an unresolved matter of concern regarding adverse outcomes. This case study aimed to evaluate the effectiveness of blinatumomab, with or without door lymphocyte infusion (DLI), in treating measurable residual disease (MRD)-positive B-ALL. Methods: All patients who received blinatumomab salvage therapy were included in this study. Eleven patients were included in the study. All patients were evaluated for MRD-negativity. Results: Before starting blinatumomab therapy, seven patients tested positive for MRD, three tested negative, and one had refractory disease. Hematopoietic cell transplantation (HCT) was reserved for five patients with persistent MRD. Six patients became MRD-negative and subsequent HCT was not performed. Only two patients relapsed; one patient died of relapse, and the other one received carfilzomib-based therapy and was MRD-negative thereafter. Nine patients were MRD-negative at a median follow-up of 28 months (15–52 months). Two of three MRD-positive post-transplant patients remained in complete molecular remission after preemptive DLI at the last follow-up date. In the first salvage, blinatumomab may achieve complete remission and bridging to HCT in pediatric patients with end-of-induction MRD-positive B-cell precursor ALL. Conclusions: The decision on how to treat post-transplant relapse continues to affect survival outcomes. Blinatumomab combined with DLI may extend the armamentarium of release options for high-risk pediatric patients. This approach is encouraging for high-risk ALL patients who are MRD-positive post-transplantation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity.

Author

Liu, Hsi‐Che, Huang, Ying‐Jung, Jaing, Tang‐Her, Wu, Kang‐Hsi, Chen, Shih‐Hsiang, Wang, Shih‐Chung, Yeh, Ting‐Chi, Hsiao, Chih‐Cheng, Chang, Te‐Kau, Yen, Hsiu‐Ju, Huang, Fang‐Liang, Lin, Pei‐Chin, Hou, Jen‐Yin, Sheen, Jiunn‐Ming, Liao, Yu‐Mei, Chang, Tsung‐Yen, Chen, Yu‐Chieh, Chiou, Shyh‐Shin, Yang, Chao‐Ping, and Pui, Ching‐Hon

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, OPTIMISM, OVERALL survival, PEDIATRICS
Abstract

Summary: This study investigates the potential utility of IKZF1 deletion as an additional high‐risk marker for paediatric acute lymphoblastic leukaemia (ALL). The prognostic impact of IKZF1 status, in conjunction with minimal/measurable residual disease (MRD), was evaluated within the MRD‐guided TPOG‐ALL‐2013 protocol using 412 newly diagnosed B‐ALL patients aged 1–18. IKZF1 status was determined using multiplex ligation‐dependent probe amplification. IKZF1 deletions, when co‐occurring with CDKN2A, CDKN2B, PAX5 or PAR1 region deletions in the absence of ERG deletions, were termed IKZF1plus. Both IKZF1 deletion (14.6%) and IKZF1plus (7.8%) independently predicted poorer outcomes in B‐ALL. IKZF1plus was observed in 4.1% of Philadelphia‐negative ALL, with a significantly lower 5‐year event‐free survival (53.9%) compared to IKZF1 deletion alone (83.8%) and wild‐type IKZF1 (91.3%) (p < 0.0001). Among patients with Day 15 MRD ≥0.01%, provisional high‐risk patients with IKZF1plus exhibited the worst outcomes in event‐free survival (42.0%), relapse‐free survival (48.0%) and overall survival (72.7%) compared to other groups (p < 0.0001). Integration of IKZF1plus and positive Day 15 MRD identified a subgroup of Philadelphia‐negative B‐ALL with a 50% risk of relapse. This study highlights the importance of assessing IKZF1plus alongside Day 15 MRD positivity to identify patients at increased risk of adverse outcomes, potentially minimizing overtreatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan

Author

Yang, Yung-Li, Jaing, Tang-Her, Chen, Shih-Hsiang, Liu, Hsi-Che, Hung, Iou-Jih, Lin, Dong-Tsamn, Yang, Chao-Ping, Peng, Ching-Tien, Lin, Kai-Hsin, Hsiao, Chih-Cheng, Jou, Shiann-Tarng, Chen, Jiann-Shiuh, Lin, Ming-Tsan, Wang, Shih-Chung, Chang, Te-Kau, Huang, Fang-Liang, Cheng, Chao-Neng, Wu, Kang-Hsi, Sheen, Jiunn-Ming, Chen, Shu-Huey, Lu, Meng-Yao, Hung, Giun-Yi, Yen, Hsiu-Ju, Hsieh, Yuh-Lin, Wang, Jinn-Li, Chang, Yu-Hsiang, Chang, Hsiu-Hao, Yeh, Ting-Chi, Weng, Te-Fu, Hou, Jen-Yin, Chen, Bow-Wen, Chen, Rong-Long, Wang, Lin-Yen, Ho, Wan-Ling, Chen, Yu-Chieh, Cheng, Shin-Nan, Chao, Yu-Hua, Yang, Shang-Hsien, Huang, Ting-Huan, Chou, Shu-Wei, Lin, Chien-Yu, Chen, Hsuan-Yu, Chao, Yu-Mei Y., Liang, Der-Cherng, and Chang, Tai-Tsung

Published
2021
Full Text
View/download PDF

29. A case series and literature review on 98 pediatric patients of germ cell tumor developing growing teratoma syndrome

Author

Hiseh, Ming‐Yun, primary, Chen, Hsin‐Hung, additional, Lee, Chih‐Ying, additional, Hung, Giun‐Yi, additional, Chang, Tsung‐Yen, additional, Chen, Shih‐Hsiang, additional, Lai, Jin‐Yao, additional, Jaing, Tang‐Her, additional, Cheng, Chao‐Neng, additional, Chen, Jiann‐Shiuh, additional, Tsai, Hsin‐Lin, additional, Yu, Ting‐Yen, additional, Hou, Ming‐Hsin, additional, Ho, Cheng‐Yin, additional, and Yen, Hsiu‐Ju, additional

Published
2023
Full Text
View/download PDF

32. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.

Author

Shen, Ming‐Ching, Chou, Sheng‐Chieh, Chiou, Shyh‐Shin, Lin, Pei‐Chin, Chen, Yeu‐Chin, Lin, Hsuan‐Yu, Lee, Yang‐Cheng, Huang, Cih‐En, Weng, Te‐Fu, Huang, Ting‐Huan, Chung, Chih‐Yuan, Chen, Jiann‐Shiuh, Chen, Shu‐Huey, Cheng, Shin‐Nan, Hsiao, Chih‐Cheng, Huang, Yen‐Min, Chen, Shih‐Hsiang, Yu, Yuan‐Bin, Lin, Shih‐Chiang, and Lin, Ching‐Yeh

Subjects
EMICIZUMAB, HEMOPHILIACS, BLOOD coagulation factor VIII antibodies, PREVENTIVE medicine, PATIENT experience
Abstract

Introduction: Emicizumab mimicking the cofactor function of activated factor VIII (FVIII) restores haemostasis. Methods: This nationwide observational study aimed to retrospectively investigate efficacy, safety, and cost in 1 year before and up to 3 years after emicizumab prophylaxis for haemophilia A (HA) patients with FVIII inhibitors. Results and discussion: A total of 39 severe HA patients with a median age of 23.0 years were enrolled. The median historical peak FVIII inhibitor titre was 174.2 BU/mL with an interquartile range of 56.5–578.8 BU/mL. The median annualized bleeding rate reduced from 24 to 0 events in the first year after emicizumab prophylaxis (p <.01) and sustained in the second and third years. The median annualized joint bleeding rate reduced to 0 and maintained up to 3 years (p <.01). Twenty‐seven patients (69.2%) had target joints before emicizumab prophylaxis and only seven patients (17.9%) of them had target joints after prophylaxis. Medical costs, including cost of haemostatic therapy, frequency of outpatient department visits, emergency room visits and hospital admission, were significantly reduced after emicizumab prophylaxis (p <.01). FVIII inhibitor titre decreased after emicizumab prophylaxis. Overall, three (7.7%) patients experienced 202 grade 1 drug‐related adverse events after emicizumab prophylaxis. No serious adverse events were reported during emicizumab prophylaxis period. The adherence to emicizumab prophylaxis was 100% up to 3 years. Conclusions: HA patients with FVIII inhibitors treated with emicizumab prophylaxis resulted in a significant reduction in treated bleeds and associated costs. No new safety events were observed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. A case series and literature review on 98 pediatric patients of germ cell tumor developing growing teratoma syndrome.

Author

Hsieh, Ming‐Yun, Chen, Hsin‐Hung, Lee, Chih‐Ying, Hung, Giun‐Yi, Chang, Tsung‐Yen, Chen, Shih‐Hsiang, Lai, Jin‐Yao, Jaing, Tang‐Her, Cheng, Chao‐Neng, Chen, Jiann‐Shiuh, Tsai, Hsin‐Lin, Yu, Ting‐Yen, Hou, Ming‐Hsin, Ho, Cheng‐Yin, and Yen, Hsiu‐Ju

Subjects
CHILD patients, LITERATURE reviews, GERM cell tumors, TERATOMA, SURVIVAL rate, CANCER cells
Abstract

Introduction: Malignant germ cell tumors (MGCTs) can develop either extracranially or intracranially. Growing teratoma syndrome (GTS) may develop in these patients following chemotherapy. Reports on the clinical characteristics and outcomes of GTS in children with MGCTs are limited. Methods: We retrospectively collected the data, including the clinical characteristics and outcomes of five patients in our series and 93 pediatric patients selected through a literature review of MGCTs. This study aimed to analyze survival outcomes and risk factors for subsequent events in pediatric patients with MGCTs developing GTS. Results: The sex ratio was 1.09 (male/female). In total, 52 patients (53.1%) had intracranial MGCTs. Compared with patients with extracranial GCTs, those with intracranial GCTs were younger, predominantly boys, had shorter intervals between MGCT and GTS, and had GTS mostly occurring over the initial site (all p < 0.001). Ninety‐five patients (96.9%) were alive. However, GTS recurrence (n = 14), GTS progression (n = 9), and MGCT recurrence (n = 19) caused a substantial decrease in event‐free survival (EFS). Multivariate analyses showed that the only significant risk factors for these events were incomplete GTS resection and different locations of GCT and GTS. Patients without any risk had a 5‐year EFS of 78.8% ± 7.8%, whereas those with either risk had 41.7% ± 10.2% (p < 0.001). Conclusion: For patients with high‐risk features, every effort should be made to closely monitor, completely remove, and pathologically prove any newly developed mass to guide relevant treatment. Further studies incorporating the risk factors into treatment strategies may be required to optimize adjuvant therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Comparison of [3H]-Thymidine, Carboxyfluorescein Diacetate Succinimidyl Ester and Ki-67 in Lymphocyte Proliferation

Author

Lee, Hsin-Ju, Gau, Chun-Chun, Lee, Wan-Fang, Lee, Wen-I, Huang, Jing-Long, Chen, Shih-Hsiang, Yeh, Ho-Yu, Liang, Chi-Jou, and Fu, Shih-Hang

Subjects
Pediatrics, Perinatology and Child Health
Abstract

BackgroundPatients with T cell deficiency 3H]-thymidine.”MethodsRadioactive [3H]-thymidine, non-radioactive carboxyfluorescein diacetate succinimidyl ester (CFSE), and Ki-67 protein expressions were used to measure the lymphocyte proliferation as calculated using the stimulation index (SI), subtraction percentage, and proliferation index (FlowJo software). Normal references were established for comparison in the absence of parallel healthy controls.ResultsNormal ranges of mitogen-stimulated lymphocyte proliferation were established as a SI of 15–267 (CSFE 47–92%, Ki-67 42–79%) with phytohemagglutinin (PHA) 5 μg/ml stimulation; 19–139 (CFSE 62–83%, 45–74% Ki-67) with concanavalin-A (ConA) 5 μg/ml stimulation; 7–53 (CFSE 6–23%, Ki-67 10–24%) with pokeweed mitogen (PWM) 0.1 ug/ml stimulation; 3–28 (CFSE 4–10%, Ki-67 5–14%) with candida 10 ug/ml stimulation; and 2–27 (CFSE 6–41%, Ki-67 6–30%) with bacille Calmette-Guerin (BCG) 0.02 ng/ml stimulation. The normalized CFSE-proliferation index was between 2.1 and 3.0. Although there was no significant correlation between these three assays in the healthy controls, the SI value for 3H]-thymidine proliferation in those with T cell deficiency was compatible with CFSE- and Ki-67-stained lymphocyte percentages, and validated in patients withIL2RG, RAG1, andZAP70mutations. When calculating [3H]-thymidine ConclusionThe large quantitative value of radioactive [3H]-thymidine was more easily recognizable than that for non-radioactive CFSE and Ki-67. Even though the correlation was not significant, those identified to have 3H]-thymidine could be consistently detected by CFSE and Ki-67, and consequently indicated for HSCT.

Published
2022

49. Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL‐2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation

Author

Li, Meng‐Ju, Liu, Hsi‐Che, Yen, Hsiu‐Ju, Jaing, Tang‐Her, Lin, Dong‐Tsamn, Yang, Chao‐Ping, Lin, Kai‐Hsin, Hung, Iou‐Jih, Jou, Shiann‐Tarng, Lu, Meng‐Yao, Hsiao, Chih‐Cheng, Peng, Ching‐Tien, Chang, Tai‐Tsung, Wang, Shih‐Chung, Lin, Ming‐Tsan, Chen, Jiann‐Shiuh, Chang, Te‐Kau, Hung, Giun‐Yi, Wu, Kang‐Hsi, Yang, Yung‐Li, Chang, Hsiu‐Hao, Chen, Shih‐Hsiang, Yeh, Ting‐Chi, Cheng, Chao‐Neng, Lin, Pei‐Chin, Chiou, Shyh‐Shin, Sheen, Jiunn‐Ming, Cheng, Shin‐Nan, Chen, Shu‐Huey, Chang, Yu‐Hsiang, Ho, Wan‐Ling, Chao, Yu‐Hua, Chen, Rong‐Long, Chen, Bow‐Wen, Wang, Jinn‐Li, Hsieh, Yuh‐Lin, Liao, Yu‐Mei, Yang, Shang‐Hsien, Chang, Wan‐Hui, Chao, Yu‐Mei Y., and Liang, Der‐Cherng

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results